TITLE

Pharmaceutical policy regarding generic drugs in Belgium

AUTHOR(S)
Simoens, Steven; De Bruyn, Kristien; Bogaert, Marc; Laekeman, Gert
PUB. DATE
May 2005
SOURCE
PharmacoEconomics;2005, Vol. 23 Issue 8, p755
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Pressure to control pharmaceutical expenditure and price competition among pharmaceutical companies are fuelling the development of generic drug markets in EU countries. However, in Belgium, the market for generic drugs is underdeveloped compared with other countries. To promote the use of generic drugs, the government introduced a reference pricing (RP) scheme in 2001. The aim of this paper is to discuss Belgian pharmaceutical policy regarding generic drugs and to analyse how the Belgian drug market has evolved following initiation of the RP scheme. The market share held by generic drugs increased following implementation of the RP scheme. Focusing on volume, average market share (by semester) for generic drugs amounted to 2.05% of the total pharmaceutical market from January 1998 to June 2001, compared with 6.11% from July 2001 to December 2003. As new generic drugs are introduced, their market share tends to increase in the first couple of months, after which it levels off. Faced with increasing generic competition, some manufacturers have launched new variants of their original drug, thereby effectively extending the period of patent protection. Strategies consisting of price reductions in return for the abolition of prescribing conditions and the launch of new dosages or formulations appear to have been successful in maintaining the market share of original drugs. Nevertheless, the introduction of the RP scheme was associated with savings amounting to 1.8% of pharmaceutical expenditure by the third-party payer in 2001 and 2.1% in 2002. The findings of this paper indicate that the RP scheme has stimulated the Belgian generic drug market. However, existing policy has largely failed to take into account the role that physicians and pharmacists can play in stimulating generic drug use. Therefore, further development of the Belgian generic drug market seems to hinge on the creation of appropriate incentives for physicians to prescribe, and for pharmacists to dispense, generic drugs. With respect to incentives to advance generic drug use, EU countries have experimented with various forms of budget constraints for physicians, generic substitution by pharmacists and RP schemes, although more evidence is needed of their impact on consumption and prices of generic drugs, pharmaceutical expenditure and health outcomes.
ACCESSION #
18475814

 

Related Articles

  • Multisource drug policies in Latin America: survey of 10 countries. Homedes, Nüria; Ugalde, Antonio // Bulletin of the World Health Organization;Jan2005, Vol. 83 Issue 1, p64 

    Essential drug lists and generic drug policies have been promoted as strategies to improve access to pharmaceuticals and control their rapidly escalating costs. This article reports the results of a preliminary survey conducted in 10 Latin American countries. The study aimed to document the...

  • Generic substitution may become EC law. Taylor, David // BMJ: British Medical Journal (International Edition);6/13/92, Vol. 304 Issue 6841, p1529 

    Reports the adoption of generic substitution policy by pharmacists in Great Britain. Decision of the European Commission for the extension of the terms of medicine patent; Discussion on generic substitution by the British Pharmaceutical Industry; Reasons behind adoption of generic substitution...

  • FDA Completes Recommendations for Three Drug User Fee Programs.  // American Family Physician;2/15/2012, Vol. 85 Issue 4, p314 

    The article reports the completion of recommendations by the U.S. Food and Drug Administration (FDA) for the fifth authorization of the Prescription Drug User Fee Act, the proposed Generic Drug User Fee program, and the proposed Biosimilar and Interchangeable Products User Fee program.

  • WHO PLEDGES TO HELP POORER COUNTRIES WITH ACCESS TO GENERIC DRUGS.  // Indian Journal of Medical Sciences;Oct2003, Vol. 57 Issue 10, p469 

    Reports on the efforts of the World Health Organization (WHO) to call for a speedy implementation of a new agreement allowing countries without proper capacity for pharmaceutical production to import cheaper generic drugs. Terms of the agreement; Need for countries to review the full range of...

  • Definición de medicamento genérico ¿un fin o un medio? Análisis de la regulación en 14 paises de la Región de las Américas. González, Claudia Patricia Vacca; Fitzgerald, James F.; Bermúdez, Jorge A. Z. // Revista Panamericana de Salud Publica;Nov2006, Vol. 20 Issue 5, p314 

    Objectives. To characterize current regulatory practices and trends relating to competing medications in 14 Latin American and Caribbean countries. Methods. Between July 2004 and April 2005 we collected information on national regulations and policies that established or contained a definition...

  • Best may be yet to come for generic drug makers. Kirsche, Michelle L. // Drug Store News;2/14/2005, Vol. 27 Issue 2, p28 

    Reports on the research-and-development pipeline of drug makers in the U.S. Sales of generic companies; Factors contributing to the performance of drug makers; Development of generic pipeline.

  • GPhA bullish on generic industry's future. Cohen, Harold E. // Drug Topics;5/7/2001, Vol. 145 Issue 9, p64 

    Provides information on the Generic Pharmaceutical Association (GPhA), a unification of the generic industry in the United States. Significance of the formation of a united front for the generic industry; Goals of the association; Strategy of pharmacy benefit managers.

  • Is the Generics Industry Ready for Multi-Source Biologics? Challener, Cynthia // Chemical Market Reporter;04/23/2001, Vol. 259 Issue 17, p14 

    Deals with the generic biologic industry. Estimated growth of the biopharmaceutical generics market; Details on the acquisition of Indiana Protein Technologies by Ivax Corp.; European firms preparing to participate in the marketing and sales of generic biopharmaceuticals; Risks faced by a...

  • Keeping costs down. Hlaves, Dale W. // Smart Business Akron/Canton;Jun2009, Vol. 19 Issue 1, p34 

    An interview with pharmacy executives Michelle Dittrich and Tracy Dankoff is presented. When asked what integrated pharmacy management (PM) is, they reply that it is a way of managing a prescription drug plan including building a pharmacy network and determining the most appropriate plan for...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics